This approval paves the way for the launch of YESAFILI in Canada, scheduled for 04 July 2025. YESAFILI is the first ...

Eylea 8 mg is the first and only anti-vascular endothelial growth factor (VEGF) treatment in the EU with treatment intervals of up to 6 months for both patients with nAMD and DME.

Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is spearheading a study titled ...

Bengaluru: Biocon Biologics Ltd ., a fully integrated global biosimilars company and a subsidiary of Biocon Ltd ., has ...

TORONTO, Ontario, Canada and BENGALURU, Karnataka, India, June (GLOBE NEWSWIRE) -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: ...

Patients had a small but nonsignificant survival advantage when continuing with anti-VEGF therapy in the second-line instead ...

Biocon Biologics secures Health Canada approval for Yesafili, the first biosimilar to Eylea® in Canada, with a global launch ...

New research has found that the endothelial cell-specific A disintegrin and metalloproteinase domain-containing protein 10 ...